- Acquired by Venus Medtech, Mar 2022
- Raised $40M funding round, Aug 2020
- Raised $5.5M funding round, Nov 2016
About
Cardiovalve is developing cardiovascular replacement devices for minimally invasive surgery. Its flagship system is designed to replace the mitral valve using a transfemoral system. Cardiovalve is designed from the bottom up for transfemoral/transseptal delivery with femoral venous access. This approach offers significant benefits including a short profile for minimal protrusion to the left ventricle, minimizing interference in the cardiac blood flow, and increased safety. The company aims to bring to market a viable, clinically proven transfemoral alternative to open-heart surgery in which mitral regurgitation treatments are easier to perform for physicians, enabling patients to return to a healthy life after a quicker recovery. Cardiovalve received FDA approval for an Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement System for a tricuspid regurgitation indication. The Cardiovalve System has also been granted Breakthrough Device Designation status by the FDA. Cardiovalve is a spin-off of Valtech Cardio, which was acquired by Edwards Lifesciences in 2017.
Funding history · 2 rounds · $45.5M total
Q&A
- What is Cardiovalve's primary focus?
- Cardiovalve develops cardiovascular replacement devices for minimally invasive surgery, specifically focusing on a transfemoral system to replace the mitral valve.
- When was Cardiovalve acquired and by whom?
- Cardiovalve was acquired by Venus Medtech in March 2022.
- What is the status of Cardiovalve's FDA approvals?
- Cardiovalve received FDA approval for an Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement System and has been granted Breakthrough Device Designation status by the FDA.
- What was Cardiovalve's total funding raised before its acquisition?
- Cardiovalve raised a total of $45,483,000.
- Who were the investors in Cardiovalve's August 2020 funding round?
- In August 2020, Cardiovalve received funding from investors including Edwards Lifesciences.
- What is Cardiovalve's employee count?
- Cardiovalve has 51–200 employees.
- Who is the CEO of Cardiovalve?
- Amir Gross is the CEO of Cardiovalve and also a founder.
- What is Cardiovalve's connection to Valtech Cardio?
- Cardiovalve is a spin-off of Valtech Cardio, which was acquired by Edwards Lifesciences in 2017.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cardiovalve.com |
|---|---|
| linkedin.com/company/33191238 |
Identifiers & details
| Former names | MITRALTECH |
|---|---|
| Founded | 2010-1 |
| Employees (exact) | 51 |
| Status reason | Acquired by Venus Medtech on Mar, 2022 |
Acquisitions & public offerings
Acquired by Venus Medtech 2022-03
Radar intelligence
Patents
| EPO | 40 |
|---|
Web history (Wayback)
| Domain | cardiovalve.com |
|---|